A phase Ib/II, multicenter, open-label study of DSP-7888 dosing emulsion in combination with immune checkpoint inhibitors (CPI) nivolumab or pembrolizumab in adult patients (pts) with advanced solid tumors, including platinum-resistant ovarian cancer (PROC).

被引：0
|
作者：
Origuchi, Makoto
Korth, Chris
Li, Zhonggai
Braendle, Edgar E.
机构：
[1] Boston Biomed Inc, Cambridge, MA USA
[2] Boston Biomed Inc, Lincon, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6099
引用
收藏
页数：2
相关论文
共 19 条
  • [1] Multicenter, open-label, phase 1 study of DSP-7888 Dosing Emulsion (DSP-7888) in patients with advanced malignancies
    Groves, Morris
    Hansen, Aaron
    Harb, Wael
    Curtis, Kelly
    Koga-Yamakawa, Erina
    Origuchi, Makoto
    Li, Zhonggai
    Iglesias, Jose
    Shaib, Walid
    Spira, Alexander
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [2] Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
    Alexander Spira
    Aaron R. Hansen
    Wael A. Harb
    Kelly K. Curtis
    Erina Koga-Yamakawa
    Makoto Origuchi
    Zhonggai Li
    Bella Ertik
    Walid L. Shaib
    Targeted Oncology, 2021, 16 : 461 - 469
  • [3] Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
    Spira, Alexander
    Hansen, Aaron R.
    Harb, Wael A.
    Curtis, Kelly K.
    Koga-Yamakawa, Erina
    Origuchi, Makoto
    Li, Zhonggai
    Ertik, Bella
    Shaib, Walid L.
    TARGETED ONCOLOGY, 2021, 16 (04) : 461 - 469
  • [4] Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study
    Li, Jin
    Liu, Jihong
    Yin, Rutie
    Zou, Dongling
    Zheng, Hong
    Cao, Junning
    Chen, Zhendong
    Sun, Wei
    Gao, Yunong
    Zhang, Songling
    Zeng, Linjuan
    An, Ruifang
    Lu, Xianping
    Ye, Shuang
    Wu, Xiaohua
    MOLECULAR CANCER, 2024, 23 (01)
  • [5] An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial
    Liu, Joyce
    Gaillard, Stephanie
    Hendrickson, Andrea Wahner
    Moroney, John
    Yeku, Oladapo
    Diver, Elisabeth
    Gunderson, Camille
    Arend, Rebecca
    Ratner, Elena
    Samnotra, Vivek
    Gupta, Divya
    Evilevitch, Lena
    Wang, Sarah
    Wang, Ping
    Tang, Joseph
    Bacque, Emeline
    Liu, Xiaohong
    Konecny, Gottfried
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S17 - S18
  • [6] Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study
    Xia, L.
    Zhou, Q.
    Zhang, Y.
    Gao, Y.
    Hu, W.
    Pan, M.
    Lou, G.
    Wang, L.
    Shi, H.
    Zhu, J.
    Sun, H.
    Wang, X.
    Wang, Q.
    Wu, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S630 - S630
  • [7] An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial
    Liu, Joyce
    Gunderson, Camille
    Hendrickson, Andrea Wahner
    Ratner, Elena
    Diver, Elisabeth
    Moroney, John
    Arend, Rebecca C.
    Louie-Gao, Melinda
    Wang, Sarah
    Luptakova, Katarina
    Konecny, Gottfried E.
    CANCER RESEARCH, 2019, 79 (13)
  • [8] An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors
    Akerley, W.
    Reilley, M.
    Marabelle, A.
    Baldini, C.
    Cassier, P. A.
    Chisamore, M.
    Tang, T.
    Lautermilch, N.
    Hong, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S862 - S863
  • [9] Anlotinib (AL3818) plus pemetrexed in patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A single-arm, open-label, phase II study.
    Zhang, Yanna
    Chen, Jueming
    Wei, Wei
    Zheng, Lie
    Li, Han
    Feng, Yanling
    Wan, Ting
    Qiu, Jiaqi
    Jiang, Xingyu
    Xiong, Ying
    Li, Jundong
    Song, Libing
    Liu, Jihong
    Huang, He
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
    Su, Hao
    Shang, Xiao
    Liu, Hongruo
    Wang, Yutong
    Yu, Yang
    Xu, Yanhua
    Jiang, Kui
    Feng, Fengzhi
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2025, 17 : 325 - 333
12